close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

117.23 -2.67 (-2.23%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abivax SA - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
6 Healthcare Stocks With Strong Upward Momentum ↗
 
Via Benzinga
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Outlook For Abivax ↗
 
Via Benzinga
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. 
Via The Motley Fool
News headline image
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
From Abivax
Via GlobeNewswire
News headline image
Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
AMD To Rally More Than 47%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Is Abivax Stock Trading Higher On Monday? ↗
Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns. 
Via Benzinga
News headline image
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease ↗
The company is working on a treatment for a form of inflammatory bowel disease, a highly watched disease area. 
Via Investor's Business Daily
Topics Government
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
From Abivax
Via GlobeNewswire
News headline image
Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
From Abivax
Via GlobeNewswire
News headline image
RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Abivax Presents First Half 2025 Financial Results
From Abivax
Via GlobeNewswire
News headline image
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season
The financial markets are abuzz with significant corporate developments as several key companies navigate pivotal moments, ranging from prestigious S&P index inclusions to critical quarterly earnings... 
Via MarketMinute
Topics Artificial Intelligence ETFs Retirement
News headline image
This Stock Is Up by 800% This Year -- but Is It a Buy? ↗
This little-known biotech might still deliver strong returns. 
Via The Motley Fool
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Abivax Announces Closing of $747.5 Million Public Offering
From Abivax
Via GlobeNewswire
News headline image
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
From Abivax
Via GlobeNewswire
News headline image
Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
From Abivax
Via GlobeNewswire
News headline image
Abivax announces trading resumption of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
News headline image
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
From Abivax
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today